National internal medicine specialty society and 501(c)(3)
One uniform surface for comparison; detailed evidence is below.
The score summarizes assessed evidence; evidence coverage is reported separately.
Audited consolidated revenue categories. Dues are the largest accounting category, but the statements do not separate personally paid, employer-reimbursed, residency-program-paid, or other institutional payments.
| Accounting category | Amount | Share |
|---|---|---|
| Dues | $29.34M | 40.77% |
| Program fees | $9.47M | 13.16% |
| Registration fees | $7.74M | 10.76% |
| Subscriptions | $5.96M | 8.28% |
| Royalties | $5.32M | 7.40% |
| Rent and parking fees | $3.27M | 4.54% |
| Advertising, net | $3.06M | 4.25% |
| Other | $2.72M | 3.78% |
| Exhibits and symposia | $2.42M | 3.36% |
| Grants and contributions | $1.49M | 2.07% |
| Tuition | $951,424 | 1.32% |
| Other publications | $223,918 | 0.31% |
| Total | $71.96M | 100.00% |
ACP separately disclosed approximately $4.2 million in pharmaceutical-industry support for the relevant period, about 5.7% of consolidated revenue. This does not classify the payer behind dues, program fees, subscriptions, royalties, meetings, or other revenue.
Primary constituency: Internal medicine physicians, related subspecialists, residents, fellows, and medical students; selected affiliates outside internal medicine have more limited rights.
Physician alignment: Supportive for internists and primary care; mixed for some subspecialty, procedural, executive, and non-internal-medicine roles.
Funding model: Dues-led and diversified, with separately disclosed industry support and substantial educational, publishing, meeting, and program revenue.
Primary influence: Board of Regents formally; elected Governors as member conduit; EVP/CEO and staff operationally; dues and program customers financially, with disclosed industry support as a minority share.
The American College of Physicians is a physician-led internal medicine specialty society with approximately 163,000 members. Its Board of Regents governs policy and business affairs, elected Governors provide a member-conduit structure, and LeRoi Hicks became EVP/CEO on July 6, 2026. FY2025 audited consolidated revenue was $71.96 million, led by $29.34 million in dues. ACP also publishes a separate industry-support schedule identifying approximately $4.2 million in pharmaceutical support, about 5.7% of consolidated revenue. The evidence supports strong mission alignment on internist education, payment, prior authorization, workforce, patient access, and evidence-based policy. The main limitations are payer identity, customer concentration, and segment-level participation and outcomes. The B grade is generally favorable while remaining specific to internal medicine rather than physicians broadly.
One sentence: ACP is a physician-governed, dues-led internal medicine society with strong mission alignment and unusually useful industry disclosures, while ultimate payer concentration and segment-level participation remain incomplete.
Every organization uses the same twelve evidence sections and order.
Conclusion: ACP is a U.S. tax-exempt 501(c)(3) medical specialty society whose formal center of gravity is internal medicine. ACP describes a current community of 163,000 internal medicine physicians, subspecialists, residents, fellows and medical students worldwide. [1] [2] [14]
Primary constituency classification: individual internal medicine physicians and related subspecialists, with trainee/student membership and selected affiliate categories. Confidence: high.
Best current financial source: ACP’s FY2025 consolidated statements were presented as audited and accompanied by an unqualified BDO opinion. Revenue was $71.96M, expenses were $95.62M, investment activity was $15.37M, and net assets declined $4.50M to $144.98M. [11] [12] [13]
Why two sets of totals appear: the audited consolidated statements and the parent 501(c)(3) Form 990 use different reporting scopes and presentations. The Form 990 reported $72.51M revenue, $91.52M expenses and a $19.01M tax-return deficit; the audited statement separately shows operating revenue, expenses, investment activity and a $4.50M change in net assets. They should not be forced into one chart. [12] [14]
Conclusion: accounting source identification is good; ultimate payer identification is incomplete. Dues are the largest accounting category, but “dues” does not establish who wrote the check. Residency programs can use group billing, demonstrating at least one institutional payment pathway. [12] [36]
| Question | Evidence-supported answer | Confidence |
|---|---|---|
| Individual physician-paid share | Unknown. Current dues rates and individual billing exist, but no aggregate payer split is public. | High confidence that public aggregate is absent |
| Hospitals or health systems | Unknown. Leader employment and member reimbursement possibilities are not evidence of payment. | High |
| Physician groups or training programs | At least some program group billing exists; total amount and share are unknown. | High |
| Pharmaceutical industry | $4.2M, 5.7% of FY2024/25 consolidated revenue, specifically disclosed. | High |
| Insurers, PBMs and device firms | No comprehensive payer-class total found. | Moderate |
| Unidentified by payer class | Cannot be converted into one reliable percentage because the available payer disclosure overlaps accounting categories. | High |
Largest specifically quantified external payer class found: pharmaceutical industry at 5.7%. This does not prove it is the largest ultimate payer class; it is the largest class ACP specifically quantified in the reviewed payer disclosure. [15]
| Entity | Role | Latest reported financial/political fact | Separation rule |
|---|---|---|---|
| American College of Physicians, Inc. | 501(c)(3) medical specialty society | FY2025 audited consolidated statements; separate Q2 2026 LDA expense $85,552. | Do not merge parent tax-return totals with ACP Services or PAC receipts. |
| American College of Physician Services, Inc. | 501(c)(6) advocacy arm; ACP members automatically participate through dues allocation | FY2025 revenue $2.90M, expenses $2.65M; Q2 2026 LDA expense $391,703. [19] [20] [22] | Separate tax entity and lobbying filing. |
| ACP Services PAC | Federal connected PAC sponsored by ACP Services | Through May 31, 2026: $336,556 receipts and $316,290 disbursements; reported contributions were individual. [23] | PAC funds are not ACP operating revenue. |
| Chapters | Regional governance and member engagement network | ACP reports 84 chapters; national dues include allocations to local chapters where applicable. [3] [4] | Chapter finances are not assumed to be parent revenue. |
A current national foundation was not combined with ACP because the reviewed current official entity descriptions and latest filings did not establish a single active foundation whose finances should be consolidated into this report.
| Influence source | Classification | Evidence and interpretation |
|---|---|---|
| Board of Regents | Directly documented | Controls business, affairs and policy; highest formal governance influence. [5] |
| CEO and senior staff | Directly documented | Runs operations and implements Board policy; highest operational influence. [9] [10] |
| Board of Governors and chapters | Directly documented | Popularly elected Governors represent member concerns and advance resolutions, but remain advisory to the Regents. [5] [7] |
| Dues-paying membership | Directly documented relationship | Dues are 40.8% of audited operating revenue. Financial dependence is meaningful, but payer identity and voting participation are not public. [12] |
| Pharmaceutical and corporate partners | Directly documented relationship; potential incentive | Industry support was 5.7%; Roundtable members meet governance/staff; 2026 Leadership Day had named corporate supporters. This shows access and support, not control. [15] [17] [24] |
| Employers of physician leaders | Directly documented relationship | Disclosure forms list academic systems, health systems, private practice, Kaiser Permanente and other roles. Employment alone does not establish institutional control. [18] |
| Single dominant payer or donor | Unknown | No public payer-class or top-supporter concentration schedule was found. |
| Speculative personal or political networks | Excluded | No influence claim was made from acquaintance, prestige, ideology or unsupported commentary. |
| Stated commitment | Relevant action or omission | Assessment | Confidence |
|---|---|---|---|
| Quality, effectiveness and professionalism | Clinical guidance, Annals, education, ethics structures and evidence-based vaccine litigation. [1] [33] | Supported | High |
| Advocacy for internal medicine | Payment, prior authorization, workforce, patient access, 10,700 lawmaker messages and 444 congressional meetings. [25] [26] [28] | Supported | High |
| Career fulfillment and practice support | Coding, contract review, coaching, financial tools, quality improvement and digital-health resources. [32] | Supported | High |
| Transparency and independence | Audited statements, industry schedule and conflict policy are public; ultimate payer classes, current-year conflict packet and concentration are incomplete. [11] [15] [16] [18] | Partially supported | High |
| Representing internal medicine broadly | Formal structure and programming span primary care, subspecialties, trainees and global chapters; segment-level voting, satisfaction and payer data are not public. [2] [4] | Supported with measurement gaps | Moderate |
| Financial stewardship | Clean audit and large net assets; FY2025 included a major planned MKSAP expense recognition and $4.5M net-asset decline. [11] [12] | Supported, with sustainability watch item | High |
Mission-conflict status: minor. No severe documented contradiction was identified. The most important tension is not a proved conflict of mission, but incomplete payer and concentration transparency alongside formal commercial relationships.
| Physician role | Signal | Strongest support | Strongest divergence or limitation | Confidence |
|---|---|---|---|---|
| Individual internist | Supportive | National advocacy, evidence-based clinical resources, dues-funded member benefits, and formal physician governance directly address internist work and professional voice. | ACP does not publish a payer-class breakdown showing how much membership is personally paid versus reimbursed or purchased by employers. | High |
| Primary care internist | Supportive | Payment reform, prior-authorization reduction, whole-person care, and workforce priorities consistently favor primary care sustainability. | Policy victories are described mainly as organizational outputs; public evidence does not quantify practice-level financial improvement for a representative primary care cohort. | High |
| Employed internist | Supportive | ACP supports protected concerted activity, responsible collective bargaining, practicing-physician participation in leadership, and reduced administrative burden. | ACP is an association, not the physician’s employer or bargaining agent; public data do not show employer-by-employer enforcement or outcomes. | Moderate |
| Independent or practice-owning internist | Supportive | Payment, coding, contract, private-equity, prior-authorization, and joint-negotiation positions address independent-practice viability. | The membership and revenue disclosures do not quantify independent-practice representation, voting participation, or dues share. | Moderate |
| Internal-medicine subspecialist or proceduralist | Mixed | ACP includes related subspecialists, publishes specialty-relevant science, and advocates broadly on payment and administrative burden. | ACP welcomed primary-care-oriented 2026 payment changes while warning that an efficiency adjustment could adversely affect some subspecialists; relative-payment interests may diverge. | Moderate |
| Rural or community internist | Supportive | Workforce, payment, telehealth, training, and underserved-care priorities are directionally aligned with rural practice viability. | Public reporting does not isolate rural-member participation, funding, retention, or measured practice outcomes. | Moderate |
| Academic internist | Supportive | Scientific publication, guidelines, teaching resources, trainee policy, and committee pathways strongly align with academic medicine roles. | Academic institutions employ many leaders, but employment relationships do not establish institutional control; representation by institution is not quantified. | Moderate |
| Trainee or early-career internist | Supportive | ACP provides trainee membership, educational benefits, councils and designated committee seats, and advocacy on loans, immigration, and workforce pipelines. | Residency programs can purchase memberships in bulk, and public records do not separate trainee-paid from program-paid dues or national voting power by trainee category. | Moderate |
| Physician executive or medical-group leader | Mixed | ACP offers evidence, workforce, payment, quality-improvement, digital-health, and policy resources useful to organizational leaders. | ACP’s physician-professional positions can diverge from employer priorities on payment allocation, workforce control, consolidation, scope, or collective action. | Moderate |
| Physician outside internal medicine | Not demonstrated | Some ACP policies may indirectly benefit all physicians, including administrative-burden and patient-access work. | ACP is formally built for internal medicine; physician affiliates outside qualifying specialties cannot vote, hold office, or attain Fellowship. | High |
| Issue | Segment | Signal | Evidence-calibrated conclusion | Confidence |
|---|---|---|---|---|
| Payment and sustainability | Primary care internists | Supportive | Persistent advocacy for inflation updates, advanced primary care and budget-neutrality reform. [26] | High |
| Relative payment allocation | Some subspecialists/proceduralists | Mixed | ACP supported primary-care-oriented changes but acknowledged possible adverse efficiency-adjustment effects on some subspecialists. [27] | Moderate |
| Prior authorization and administrative burden | All practicing internists | Supportive | Documented toolkits and advocacy seek to reduce paperwork and reform prior authorization. [25] [28] | High |
| Employment voice and collective action | Employed physicians | Supportive | ACP supports protected concerted activity, responsible collective bargaining and practicing-physician leadership. [29] | High |
| Independent-practice viability and consolidation | Independent physicians | Supportive | Payment, contract, coding, private-equity and joint-negotiation positions are directionally supportive; practice-level outcomes are not quantified. [25] [29] [32] | Moderate |
| Scope and team leadership | Physicians generally | Supportive | ACP favors physician-led team care over broad independent nonphysician practice expansion. [30] | High |
| Education and continuous learning | Internists and trainees | Supportive | Extensive learning, publication and career resources are documented; burden and effectiveness of certification-related tools are not independently measured. [4] [32] | Moderate |
| Patient access and public health | Internists and patients | Supportive | ACP advocates on coverage, Medicare Advantage, vaccines and evidence-based public health. [25] [31] [33] | High |
| Representation of non-internists | Physicians outside internal medicine | Not demonstrated | Some policies have spillover benefit, but formal membership rights and mission remain internal-medicine centered. [2] [3] | High |
Legal/regulatory conclusion: no material current adverse finding identified; confidence moderate because an internet-accessible public-record review is not equivalent to a nationwide docket and regulatory certification search.
The numerical result is an Evidence & Accountability Grade, not an endorsement, moral verdict or physician-support grade. All eight required dimensions had enough evidence to score; none was normalized away.
| Dimension | Score | Grade logic | Material contrary evidence/unknown |
|---|---|---|---|
| Financial transparency & source identification | 12/15 | Audited statements, Form 990, and an industry-support schedule are public; payer classes and current donor/counterparty concentration remain incomplete. | Payer or segment detail remains incomplete. |
| Funding independence & concentration risk | 12/15 | Dues are the largest accounting category and disclosed pharmaceutical support is 5.7% of FY2024/25 consolidated revenue, but ultimate payer concentration is indeterminate. | Payer or segment detail remains incomplete. |
| Mission-to-action alignment | 18/20 | Education, evidence-based policy, payment, prior-authorization, workforce, and patient-access work substantially track the stated mission. | See detailed sections for limitations. |
| Physician/member governance & representation | 12/15 | Physicians govern the main board and elected Governors transmit member concerns, although national policy authority is indirect and concentrated in the Board of Regents. | See detailed sections for limitations. |
| Breadth across physician segments | 8/10 | The record is broad within internal medicine and includes trainees, international members, primary care, and subspecialties; it is not designed to represent all physicians. | Payer or segment detail remains incomplete. |
| Leadership, conflicts & accountability | 8/10 | Conflict policies and disclosures exist, but the public disclosure packet lags the current governance year and leadership webpages were not synchronized with the CEO transition. | See detailed sections for limitations. |
| Legal, regulatory & ethical record | 8/10 | No material final adverse federal enforcement finding was identified in the reviewed sources; current litigation reviewed places ACP as a plaintiff, not an enforcement target. | No score was based solely on absence of an enforcement finding. |
| Outcomes & public accountability | 4/5 | ACP reports participation, educational reach, advocacy contacts, and audited finances; independent outcome evaluation and segment-level satisfaction data are limited. | See detailed sections for limitations. |
Weighted evidence coverage: 86%. This reflects strong coverage for identity, governance, FY2025 finance, current advocacy and federal political activity; moderate coverage for payer identity, member-segment participation, conflict freshness, legal completeness and independent outcomes.
Interpretive guardrail: Nondisclosure leaves an evidence gap; it does not establish improper influence or misconduct.
Publication status: Public review. A last-link check and final editorial approval are required before each release.
Organization review: The reviewed organization did not approve, edit, or veto the score. A factual correction process is described on the Blair Compass methodology and corrections pages.
Scope: Verification is limited to publicly accessible records. Private contracts, nonpublic minutes, sealed proceedings, and undisclosed conflicts are outside the available evidence.
Source rule: Primary and official records were preferred. Accounting categories were not converted into payer identities. Related entities were kept separate. Allegations were not treated as findings.
Verification: current leaders and major financial arithmetic were checked for this publication batch. Material corrections and future updates follow the published verification process.
